Cabometyx: payments to doctors
Payments that named Cabometyx as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $16.6M
- Providers
- 10,466
- Transactions
- 52,902
- Average per transaction
- $314
The per-transaction average — $314 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 10,466 providers the average total is $1,587, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Exelixis Inc. | $16,558,714 | 99.7% |
| Ipsen Pharma SAS | $26,550 | 0.2% |
| Ipsen Innovation | $22,840 | 0.1% |
| Ipsen Biopharmaceuticals, Inc | $1,764 | 0.0% |